Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™

NCT00128583 is registered in ClinicalTrials.gov with CancerVax Corporation as lead sponsor.

NCT NCT00128583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™
Lead sponsor
CancerVax Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2005
Completion date
Not reported
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)